Awakn Life Sciences
Information
Awakn Life Sciences is a clinical-biotech company researching, developing, and delivering psychedelic New Molecular Entity drugs and therapies to treat Addiction.
We are integrating psychedelic medicine into mainstream healthcare to enable better mental health for more people through Research, Digital, Clinics, and Ecosystems.
We have a dual strategic focus, to develop and commercialise proprietary psychedelic therapies and New Molecular Entity drugs and to treat Addiction and other mental health conditions in a chain of medical psychedelic clinics across the UK and EU.
Our goals are to be the global leader in the research of psychedelic therapies and New Molecular Entity drugs to treat Addiction, build the UK and EU’s leading chain of medical psychedelic clinics, and scale our reach through our Partnerships Ecosystem.
